These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31357616)

  • 1. Proteomic Advances in Glial Tumors through Mass Spectrometry Approaches.
    Pirlog R; Susman S; Iuga CA; Florian SI
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31357616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [OMICS and biomarkers of glial tumors].
    Idbaih A
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PREDICTING SIGNIFICANCE OF UNKNOWN VARIANTS IN GLIAL TUMORS THROUGH SUB-CLASS ENRICHMENT.
    Fichtenholtz AM; Camarda ND; Neumann EK
    Pac Symp Biocomput; 2016; 21():297-308. PubMed ID: 26776195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts in the pathology and genetics of gliomas.
    Sarkar C; Jain A; Suri V
    Indian J Cancer; 2009; 46(2):108-19. PubMed ID: 19346644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Towards a molecular classification of gliomas].
    Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
    Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas.
    Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH
    J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
    Idbaih A; Marie Y; Lucchesi C; Pierron G; Manié E; Raynal V; Mosseri V; Hoang-Xuan K; Kujas M; Brito I; Mokhtari K; Sanson M; Barillot E; Aurias A; Delattre JY; Delattre O
    Int J Cancer; 2008 Apr; 122(8):1778-86. PubMed ID: 18076069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of multiple larger-sized transcripts for several genes in oligodendrogliomas: potential markers for glioma subtype.
    Xu X; Joh HD; Pin S; Schiller NI; Prange C; Burger PC; Schiller MR
    Cancer Lett; 2001 Sep; 171(1):67-77. PubMed ID: 11485829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic analysis to complement histopathological diagnosis of brain tumors.
    Nakamura M; Shimada K; Ishida E; Nakase H; Konishi N
    Histol Histopathol; 2007 Mar; 22(3):327-35. PubMed ID: 17163407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates in Pediatric Glioma Pathology.
    Hakar MH; Wood MD
    Surg Pathol Clin; 2020 Dec; 13(4):801-816. PubMed ID: 33183734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic classification of gliomas.
    Perry A; Wesseling P
    Handb Clin Neurol; 2016; 134():71-95. PubMed ID: 26948349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current classification of gliomas].
    Taillibert S; Pedretti M; Sanson M
    Presse Med; 2004 Oct; 33(18):1274-7. PubMed ID: 15611709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of nervous system tumors.
    Shapiro JR
    Hematol Oncol Clin North Am; 2001 Dec; 15(6):961-77. PubMed ID: 11770302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A; Duran-Peña A; Bonnet C; Ducray F
    Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p.
    Yang LS; Xu XE; Liu XP; Jin H; Chen ZQ; Liu XH; Wang Y; Huang FP; Shi Q
    J Proteomics; 2012 Dec; 77():480-91. PubMed ID: 23041135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
    Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
    Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
    Rousseau A; Nutt CL; Betensky RA; Iafrate AJ; Han M; Ligon KL; Rowitch DH; Louis DN
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1149-56. PubMed ID: 17146289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular biology of WHO grade II gliomas.
    Marko NF; Weil RJ
    Neurosurg Focus; 2013 Feb; 34(2):E1. PubMed ID: 23373446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.